August 29, 2026 11:55 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
VHP breaks silence on Durga Puja ‘guidelines’: No blanket non-veg ban, clarifies stand on theme pandals amid backlash | No non-veg near pandals, no ‘distorted’ idols: VHP’s Durga Puja guidelines spark Bengal debate | ‘Either they will stay, or we will’: Suvendu Adhikari's warning to Jadavpur students over 'Azadi' slogans | 'Inaccurate reports': Penguin India denies dropping Sonia Gandhi memoir | ‘Clean my shoes’: Greater Noida woman detained after alleged abuse, assault of security guards | 21-year-old model stabbed to death in Delhi; gym trainer arrested after encounter | Abhishek Banerjee, Derek O'Brien, other TMC leaders booked after Camac Street clash with Kolkata Police | Kanpur plane crash: Training aircraft crashes near Ganges, two pilots killed | Big IT boost for Bengal: LTM opens global delivery & AI centre in Kolkata's New Town | 21-year-old Delhi model found stabbed at Delhi home, gym trainer accused of killing her
Stock Market
Representational Photo: ChatGPT

Bloodbath on Dalal Street! Sensex crashes over 700 points, Nifty down 200 points amid market panic

| @indiablooms | Jan 08, 2026, at 02:08 pm

Mumbai/IBNS: The Indian stock market witnessed a sharp sell-off on Thursday, with the BSE Sensex plummeting over 700 points and the NSE Nifty 50 sliding more than 200 points, media reports said.

The indices remained under pressure throughout the morning session, with Sensex touching an intraday low of 84,230.

Among the notable laggards in the Nifty 500 were Signature Global, Hindustan Zinc, National Aluminium, NMDC, Hindustan Copper, JSL and GMDC.

At around 1:30 pm, Punjab National Bank shares fell 2.13%, while Apex Frozen Foods plunged 7.56%, intensifying the market slide.

In the morning, shares of Panacea Biotec Ltd. surged around 9 per cent on Thursday after the pharmaceutical and vaccine maker announced the completion of enrollment for the Phase III clinical trial of its dengue vaccine candidate, DengiAll.

The company has enrolled a total of 10,335 participants in the late-stage trial, marking a key milestone in the development of India’s indigenous dengue vaccine.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.